BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia.
Haley E RamseyDalton L GreenwoodSusu ZhangMerrida ChildressMaria P ArrateAgnieszka E GorskaLonda FullerYue ZhaoKristy StengelMelissa A FischerMatthew C StubbsPhillip C C LiuKelli BoydJeffrey C RathmellScott W HiebertMichael R SavonaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our findings suggest low dose combinations of venetoclax and BETi may be more efficacious for patients with AML than either monotherapy, potentially providing a longer, more tolerable dosing regimen.